{"name":"Diakonos Oncology Corporation","slug":"diakonos-oncology-corporation","ticker":"","exchange":"","domain":"diakonosoncologycorporation.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Autologous DC Therapy","genericName":"Autologous DC Therapy","slug":"autologous-dc-therapy","indication":"Advanced solid tumors","status":"phase_1"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DOC1021","genericName":"DOC1021","slug":"doc1021","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Autologous DC Therapy","genericName":"Autologous DC Therapy","slug":"autologous-dc-therapy","phase":"phase_1","mechanism":"Autologous dendritic cells are loaded with tumor antigens to stimulate a patient-specific immune response against cancer cells.","indications":["Advanced solid tumors"],"catalyst":""},{"name":"DOC1021","genericName":"DOC1021","slug":"doc1021","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPQnZJWmNYeC1EeE5PNFllY0RicUo5Y3dEcDhGOG0ybnNGMU1XTUliSE5fZzBvOXlnc01objg1V1RneGU2YWs1OUJHNVBJc0Y5LWtOZG9hay1PMWJFd2VGOE1WdjBJMDQ3T3FrWGhjTmJQODR5NjVvYzFZM1dnbXRTd3J6eTZXZS12X2g1NThaVlBQZjhOaGNQa0c4TjhKUEVmSFpKVmxTLTRSZ2phNE8xY3FzXzNKZEMyREhPeXA1aFdtUzI3OVNTZkdIMGI3em5rV3lKeWo4bGNzSGN6SlMtUWVrS21TQkdiMDhza0prVUF4eFR5RHl3?oc=5","date":"2026-02-17","type":"trial","source":"prnewswire.com","summary":"Diakonos Oncology Announces Study to Continue after First DSMB Safety Review of DOC1021 in Phase 2 GBM Study - prnewswire.com","headline":"Diakonos Oncology Announces Study to Continue after First DSMB Safety Review of DOC1021 in Phase 2 GBM Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNb3UtWF90S0E0NjRGT1NjUmJsRUhYZnVoY3J4bDJQNi1BZ05rQWw2WXkzRm50YkRWSF8tZmQ4Ymlnd2U5TjBYYXdPbjJ6NkhzNDFVLVpSaG5BeGtuQlpXb2UtLUNsRHA5V0FjazZ5SFNteWZxd1Jjd1haQTNnb3FtcndCZ1IwdmZfN0E5ckFBUUkxU1hlZGJiSlYwNjFBSWdaXzVocl8yVy1UN21lYzlvLVEwRDl1S0pNX21wTnppMFlMV3VsNkNmc045N00zWEJTcWJBSF9IbnNVZmJ3dzh3TDRXcVBmYlVK?oc=5","date":"2025-12-15","type":"pipeline","source":"prnewswire.com","summary":"Diakonos Oncology to Present Corporate Overview and Participate in Panel at 2026 Biotech Showcase - prnewswire.com","headline":"Diakonos Oncology to Present Corporate Overview and Participate in Panel at 2026 Biotech Showcase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gJBVV95cUxPM28tME9RZm5qSWlvODNsT2x2UjdqcjU0aThQbEkyNVp3azBJUGRpQnB1ZnNTU1NGUEEzS0NONE1QVlpYVllNWHBRel9rNEVMTW1qVm5ybXB4Sm9IYS1DejJ4MEJVZ2d5cjR6QU11VnFtT2gyYmJsWHVWTU1tTVBueXJCYTdXdmU2eTFteE04TGR1U3Jmb3lnLXdNWHFHeUk4ejh0LV85Sk9HOGZHcGw4T2J2TkstVTZOakNwN2FsOWJnS1lBNlBQUUdDamQ5NTU0MGh4Q1JJZ0ppclJJYUlEb0V1cHdsS2Mzak9fZ3lEVFBrVGJUVndfbEMwWkZWN1BRMG4tWmRyM0xqNGI5UUN6QU9qMzRBSk8wT1RVczJTVC02S014TmoybWhRME5YX0x3bjZXRkpPUThnZHJtVldVeF8tb2Y0QU91OU5tcmhuR013ZXJtcVBLTU9Zc3BUVHVNTEE?oc=5","date":"2025-11-07","type":"trial","source":"prnewswire.com","summary":"Diakonos Oncology Presents Promising Preliminary Data from Phase 1 Study of DOC1021 Cell-Based Immunotherapy in Pancreatic Cancer at Society for Immunotherapy of Cancer 40th Annual Meeting - prnewswir","headline":"Diakonos Oncology Presents Promising Preliminary Data from Phase 1 Study of DOC1021 Cell-Based Immunotherapy in Pancreat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxQR3FnMktkOXk3TldMNk9QcllHUU1IUEZSQjdlWnNZZm9SamtHMTMybnVUQVVwOEFHdG5TaDVsSmI1Y0RSUDNWb0Y4TVFBU2ZNWFhoN1BvMWtKbTQ4N25aeml2MklXTC10dk9JLXJLOXQ0UWFCOFlBR1ZEOVJpMk5aWUpMWkd4MlZZZ1BDUXoyX0pINjEtVG1uRzZOX0xHYXNCR1JOZi1kMkpNUmJxd2M4bDhDTUtkM2VTWm9rRUt6b09lZDdZRXhXV0l2YXNtanBlWGVRS3NTRzFPYTFxcFVGX0Q0NktLRGZRVm04b3hOVk9ENk9KT3MxX3R3ZlU4NE1fc1BvNVNvUQ?oc=5","date":"2025-07-22","type":"trial","source":"prnewswire.com","summary":"Diakonos Oncology Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating DOC1021 (dubodencel) for Glioblastoma - prnewswire.com","headline":"Diakonos Oncology Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating DOC1021 (dubodencel) for Glioblasto","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5zVHhJTjlzMm5oYnZYN2lIcVJqeldoOTZrS3Z3SzJqOTdqeFpLdXMyMy1NNElmekRYM0hDVnlqTjY4RWphdm11dDEtVkVQSHZuMkJ2LXJRUWFaZ0Q0RFJYNGNHNWtSNnE3ZXI4M1N0azV0TjVhUGdfcg?oc=5","date":"2025-06-02","type":"trial","source":"Clinical Trials Arena","summary":"Diakonos Oncology secures $20m for Phase II trial of glioblastoma treatment - Clinical Trials Arena","headline":"Diakonos Oncology secures $20m for Phase II trial of glioblastoma treatment","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-30","type":"trial","source":"prnewswire.com","summary":"Diakonos Oncology Closes $20 Million Financing to Accelerate Phase 2 Glioblastoma Clinical Development Program and Expand Use of Innovative Dendritic Cell Platform for Studies in Other Indications - p","headline":"Diakonos Oncology Closes $20 Million Financing to Accelerate Phase 2 Glioblastoma Clinical Development Program and Expan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxPMkN0MXYwV1VhRHFHM3NlVHJUb1Nyd1ROczNEbVdMaHNKVi14bnVpamVSdFp5Zlcya2xOM0kySkhNa1czanFENG5lVmw1X2Z0VmJTMzdKMENVNnpjVGdZbS1RUVlHM0dnOEJ1WExPcEpnT3dYMUJsSFVDYW44dllrWHZmOGdoN0YtSERQeENBZHFwS3VHdW9wY0FhWGx5Z3lWcG1uMG1oSVhjTlVyc25oVC1TZ3F1Z0RBYklUTE8xMlZtaEdnN0JUeDVsOXFhQkx2emJ1eUJLY1NLZEd3bm1KWlNTTE9WSXNScmhDUkZlWC0zN25LS0NBbWRkWQ?oc=5","date":"2025-04-09","type":"trial","source":"prnewswire.com","summary":"Diakonos Oncology Presents Phase I Analysis of DOC1021 at the 2025 American Academy of Neurology Annual Meeting - prnewswire.com","headline":"Diakonos Oncology Presents Phase I Analysis of DOC1021 at the 2025 American Academy of Neurology Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNc1ppWmtEZUFjYy1SVW9WREpreW5CdVF1bzV0aFJxOUppVkdwa1R6N21tZ2F0WjFOM3F1YWE3ZVF6cWNaZjZyQWlfWU5NQzNqdVBCeHR3R1ZZVnZLLUV1aUp0SU44Mm5ZTG4yV2czWW9razdKNzRReUcyTHpWdlp6U0JFbzVLcmU5eXVyTG90Vmk2YmlnVkc4?oc=5","date":"2025-03-18","type":"pipeline","source":"Pharma Voice","summary":"How non-traditional investors fuel up-and-coming biotechs when VC funding dries up - Pharma Voice","headline":"How non-traditional investors fuel up-and-coming biotechs when VC funding dries up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxQcWtjWVZROEEydmN1dnN2aURoU2wxQWE2NGlqUDFQUkxDZUQ1eWQtNEtkZldhUldoV3pUQ3EtUVVmV3Fmam80Wk00N21LMzVjcEVDLUhmY29WRnROaFN5cFMyN3dNT0JNMm5KRjd0ekh3X3BrSUlTcGZlUHhvTm9QaEdIVVIzY2UxTGdTem1KVGRNbXVQWGFZZVpMNFJUeGV2V0dfVkhTTHI3SVRBVE5HUWlDcTVOZERHd1lUWHZZQ0pLOGQ3M2JSYlpWUzBrVG9Kb3pKY2p0SzFreGh3Smt6bjdmVEtjY2lEUkVra05WeVl4VEVMYXVpbk5QclJ0dkowU1V6Mw?oc=5","date":"2023-10-10","type":"pipeline","source":"prnewswire.com","summary":"Cellipont Bioservices and Diakonos Oncology Corporation Collaborate to Develop Groundbreaking Therapy for Glioblastoma - prnewswire.com","headline":"Cellipont Bioservices and Diakonos Oncology Corporation Collaborate to Develop Groundbreaking Therapy for Glioblastoma","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}